Efficient	0	9	O
inhibition	10	20	O
of	21	23	O
ovarian	24	31	B-Pathological_formation
cancer	32	38	I-Pathological_formation
growth	39	45	O
and	46	49	O
prolonged	50	59	O
survival	60	68	O
by	69	71	O
transfection	72	84	O
with	85	89	O
a	90	91	O
novel	92	97	O
pro	98	101	O
-	101	102	O
apoptotic	102	111	O
gene	112	116	O
,	116	117	O
hPNAS	118	123	B-Gene_or_gene_product
-	123	124	I-Gene_or_gene_product
4	124	125	I-Gene_or_gene_product
,	125	126	O
in	127	129	O
a	130	131	O
mouse	132	137	B-Organism
model	138	143	O
.	143	144	O

In	145	147	O
vivo	148	152	O
and	153	156	O
in	157	159	O
vitro	160	165	O
results	166	173	O
.	173	174	O

OBJECTIVE	176	185	O
:	185	186	O
We	187	189	O
transfected	190	201	O
ovarian	202	209	B-Cell
cancer	210	216	I-Cell
cells	217	222	I-Cell
and	223	226	O
administered	227	239	O
recombinant	240	251	O
plasmid	252	259	O
encoding	260	268	O
hPNAS	269	274	B-Gene_or_gene_product
-	274	275	I-Gene_or_gene_product
4	275	276	I-Gene_or_gene_product
to	277	279	O
nude	280	284	B-Organism
mice	285	289	I-Organism
bearing	290	297	O
ovarian	298	305	B-Pathological_formation
cancer	306	312	I-Pathological_formation
,	312	313	O
aiming	314	320	O
to	321	323	O
evaluate	324	332	O
the	333	336	O
effect	337	343	O
of	344	346	O
hPNAS	347	352	B-Gene_or_gene_product
-	352	353	I-Gene_or_gene_product
4	353	354	I-Gene_or_gene_product
against	355	362	O
ovarian	363	370	B-Pathological_formation
cancer	371	377	I-Pathological_formation
in	378	380	O
vitro	381	386	O
and	387	390	O
in	391	393	O
vivo	394	398	O
.	398	399	O

METHODS	400	407	O
:	407	408	O
Ovarian	409	416	B-Cell
cancer	417	423	I-Cell
SKOV3	424	429	I-Cell
cells	430	435	I-Cell
were	436	440	O
transfected	441	452	O
with	453	457	O
hPNAS	458	463	B-Gene_or_gene_product
-	463	464	I-Gene_or_gene_product
4	464	465	I-Gene_or_gene_product
-	465	466	O
plasmid	466	473	O
,	473	474	O
and	475	478	O
cell	479	483	B-Cell
proliferation	484	497	O
was	498	501	O
evaluated	502	511	O
by	512	514	O
MTT	515	518	O
assay	519	524	O
;	524	525	O
apoptosis	526	535	O
was	536	539	O
examined	540	548	O
by	549	551	O
DNA	552	555	O
ladder	556	562	O
,	562	563	O
Hoechst33258	564	576	O
staining	577	585	O
and	586	589	O
flow	590	594	O
-	594	595	O
cytometric	595	605	O
assays	606	612	O
.	612	613	O

Nude	614	618	B-Organism
mice	619	623	I-Organism
bearing	624	631	O
ovarian	632	639	B-Pathological_formation
cancers	640	647	I-Pathological_formation
were	648	652	O
treated	653	660	O
with	661	665	O
hPNAS	666	671	B-Gene_or_gene_product
-	671	672	I-Gene_or_gene_product
4	672	673	I-Gene_or_gene_product
-	673	674	O
p	674	675	O
/	675	676	O
liposome	676	684	B-Drug_or_compound
.	684	685	O

Tumor	686	691	B-Pathological_formation
growth	692	698	O
was	699	702	O
determined	703	713	O
and	714	717	O
survival	718	726	O
was	727	730	O
recorded	731	739	O
.	739	740	O

TUNEL	741	746	O
assay	747	752	O
and	753	756	O
microvessel	757	768	B-Tissue
density	769	776	O
was	777	780	O
assessed	781	789	O
to	790	792	O
evaluate	793	801	O
apoptosis	802	811	O
and	812	815	O
angiogenesis	816	828	O
.	828	829	O

RESULTS	830	837	O
:	837	838	O
Both	839	843	O
inhibition	844	854	O
of	855	857	O
proliferation	858	871	O
(	872	873	O
p	873	874	O
<	875	876	O
0	877	878	O
.	878	879	O
05	879	881	O
)	881	882	O
and	883	886	O
induction	887	896	O
of	897	899	O
apoptosis	900	909	O
(	910	911	O
p	911	912	O
<	913	914	O
0	915	916	O
.	916	917	O
05	917	919	O
)	919	920	O
were	921	925	O
observed	926	934	O
in	935	937	O
SKOV3	938	943	B-Cell
cells	944	949	I-Cell
transfected	950	961	O
with	962	966	O
hPNAS	967	972	B-Gene_or_gene_product
-	972	973	I-Gene_or_gene_product
4	973	974	I-Gene_or_gene_product
-	974	975	O
p	975	976	O
in	977	979	O
vitro	980	985	O
.	985	986	O

In	987	989	O
hPNAS	990	995	B-Gene_or_gene_product
-	995	996	I-Gene_or_gene_product
4	996	997	I-Gene_or_gene_product
-	997	998	O
p	998	999	O
-	999	1000	O
treated	1000	1007	O
tumor	1008	1013	B-Cell
cells	1014	1019	I-Cell
in	1020	1022	O
vivo	1023	1027	O
,	1027	1028	O
tumor	1029	1034	B-Pathological_formation
growth	1035	1041	O
significantly	1042	1055	O
decreased	1056	1065	O
,	1065	1066	O
while	1067	1072	O
the	1073	1076	O
survival	1077	1085	O
time	1086	1090	O
of	1091	1093	O
tumor	1094	1099	B-Pathological_formation
-	1099	1100	O
bearing	1100	1107	O
mice	1108	1112	B-Organism
was	1113	1116	O
prolonged	1117	1126	O
compared	1127	1135	O
with	1136	1140	O
control	1141	1148	O
groups	1149	1155	O
(	1156	1157	O
p	1157	1158	O
<	1159	1160	O
0	1161	1162	O
.	1162	1163	O
05	1163	1165	O
)	1165	1166	O
.	1166	1167	O

Increased	1168	1177	O
apoptosis	1178	1187	O
of	1188	1190	O
tumor	1191	1196	B-Cell
cells	1197	1202	I-Cell
and	1203	1206	O
decreased	1207	1216	O
angiogenesis	1217	1229	O
in	1230	1232	O
tumor	1233	1238	B-Tissue
tissue	1239	1245	I-Tissue
were	1246	1250	O
also	1251	1255	O
observed	1256	1264	O
.	1264	1265	O

CONCLUSIONS	1266	1277	O
:	1277	1278	O
Our	1279	1282	O
promising	1283	1292	O
results	1293	1300	O
on	1301	1303	O
the	1304	1307	O
potential	1308	1317	O
antitumor	1318	1327	B-Pathological_formation
effects	1328	1335	O
of	1336	1338	O
hPNAS	1339	1344	B-Gene_or_gene_product
-	1344	1345	I-Gene_or_gene_product
4	1345	1346	I-Gene_or_gene_product
on	1347	1349	O
ovarian	1350	1357	B-Pathological_formation
cancer	1358	1364	I-Pathological_formation
in	1365	1367	O
vitro	1368	1373	O
and	1374	1377	O
in	1378	1380	O
vivo	1381	1385	O
may	1386	1389	O
be	1390	1392	O
explained	1393	1402	O
,	1402	1403	O
in	1404	1406	O
part	1407	1411	O
,	1411	1412	O
by	1413	1415	O
the	1416	1419	O
induction	1420	1429	O
of	1430	1432	O
apoptosis	1433	1442	O
and	1443	1446	O
inhibition	1447	1457	O
of	1458	1460	O
angiogenesis	1461	1473	O
.	1473	1474	O

Consequently	1475	1487	O
,	1487	1488	O
hPNAS	1489	1494	B-Gene_or_gene_product
-	1494	1495	I-Gene_or_gene_product
4	1495	1496	I-Gene_or_gene_product
has	1497	1500	O
potential	1501	1510	O
as	1511	1513	O
a	1514	1515	O
new	1516	1519	O
gene	1520	1524	O
therapy	1525	1532	O
for	1533	1536	O
human	1537	1542	B-Organism
ovarian	1543	1550	B-Pathological_formation
cancer	1551	1557	I-Pathological_formation
.	1557	1558	O

